In conclusion, FOXO1 plays an important regulatory role in various pro-inflammatory and glucose signaling pathways, suggesting that FOXO1 is a valuable therapeutic target for the treatment of obesity. Here, FOXO1 is linked to obesity due to melanocortin 4 receptor deficiency.